Navigation Links
Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Date:7/7/2010

=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='97916434';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.silence-therapeutics.com/">www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the Zamore "Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in ... the PandaPLUS 2000, which is ideal for new applications ... cell disruption . This compact laboratory homogenizer is the ... food, food additives and ingredients as well as for ...
(Date:1/22/2015)... January 22, 2015 Protocol Networks brings ... growing team of brand-neutral, independent consultants, Protocol Networks has ... explained that over the years, his company has attracted ... Town of Plainfield, as well as others. With the ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... NEW BRUNSWICK , Nueva Jersey , 22 ... Award for Biomedical Research abre hoy su llamada ... las personas cuya investigación científica ha hecho, o tiene ... de la salud humana. Las nominaciones se aceptarán hasta ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... YORK, May 2 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) ... Financial Officer., Pulmo BioTech Chief Executive Officer Garry McCann ... join the company and that Rajiv,s,experience and financial acumen would ... completion of its Phase I Human Trials and then into ...
... -- Quarterly Revenues Increase 62% to $11.7 million, ... million with EPS of $0.11, NEW YORK ... Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: ... products in China, today announced its financial results,for ...
... 7, 2008 at 10:00 AM EDT, CEDAR KNOLLS, ... ) will host a conference call discussing,its financial results ... May 7, 2008 at 10:00 AM EDT., A ... through the,company,s website at: http://www.emisphere.com . The live ...
Cached Biology Technology:Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... AGAWAM, Mass., May 13 Microtest Laboratories ... is adding dissolution testing to its current suite of ... services."The addition of dissolution testing ... said Steven Richter, Ph.D., President and Scientific Founder of Microtest ...
... May 20 Validus Technologies Corporation and HierStar ... formed a strategic manufacturing, marketing and distribution alliance ... Time Password (OTP) authentication products to combat cybercrime ... increasing data breaches, which have created a global ...
... scientists have identified two new genes and two new enzymes ... the plants were making monoterpenes, compounds that help give tomato ... the face of accepted thought. Such research could help ... Based on years of research, scientists thought that plants always ...
Cached Biology News:Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 2Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 3Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 2Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 3MSU discoveries upend traditional thinking about how plants make certain compounds 2
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: